Evaluating whether a concurrent retinoid x receptor agonist can enhance the efficacy of the HER2-IGFPB2-igflr vaccine in eliminating existing ductal carcinoma in situ and preventing progression of…
Ended Awarded Last action
- Contract number
- 75N91018F00009
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $930,464
Award facts
- Opportunity
-
- N01CN201500036 Solicitation number
- Contract value 100% obligated
- $930,464.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35294, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $930,464 |
About this award
This federal contract was awarded by the National Cancer Institute, part of the Department of Health and Human Services, to the University of Alabama at Birmingham (UAB) to evaluate whether a concurrent retinoid X receptor agonist can enhance the efficacy of the HER2-IGFPB2-IGFLR vaccine in eliminating existing ductal carcinoma in situ and preventing progression of invasive breast cancer. The contract, valued at $930,464.00, is a delivery order under the PREVENT Cancer Program, a preclinical cancer prevention program. UAB has subcontracted a portion of the work to the University of Washington. This contract does not have a set-aside designation.
Description
Evaluating whether a concurrent retinoid x receptor agonist can enhance the efficacy of the HER2-IGFPB2-igflr vaccine in eliminating existing ductal carcinoma in situ and preventing progression of invasive breast cancer
Quick answers
Who was awarded contract 75N91018F00009?
75N91018F00009 was awarded to University Of Alabama At Birmingham by National Cancer Institute (National Institutes of Health) on July 9, 2018.
How much is contract 75N91018F00009 worth?
The government has obligated $930,464 on 75N91018F00009.
Is contract 75N91018F00009 an order under another contract?
Yes. 75N91018F00009 is a delivery order under HHSN261201500036I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract 75N91018F00009 competed?
The extent of competition for 75N91018F00009 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award